Skip to content
Fortress Biotech, Inc.'s (NASDAQ:FBIO): Fortress Biotech, Inc. develops and commercializes pharmaceutical and......
(Bloomberg) -- AstraZeneca Plc fell from a record high in New York trading after data for the company’s Covid-19 vaccine candidate, though promising, fueled concerns about whether it can match competitors.Bernstein analysts led by Ronny Gal said the vaccine, developed in partnership with the University of Oxford, showed early positive data, but the benefits didn’t appear to match the bar set by programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.“In the competitive context they fail to impress,” Gal wrote.Exacerbating concerns, the Lancet medical journal publication came just an hour after Pfizer and BioNtech had announced early positive data from their Covid-19 vaccine trial in Germany, which builds upon promising results from their program earlier this month.U.S. listed shares of AstraZeneca fell as much as 5.7% -- the biggest intraday decline since March -- bringing the stock’s year-to-date gain to 19%. Moderna, which is among biotech’s hottest stocks,...
Convinced of Tesla Inc's imminent meteoric rise, Orestis Palampougioukis, a Netherlands-based software developer, took out a 43,000 euro ($49,000) loan in early October to invest it all in the electric carmaker, which at the time was trading at around $230 a share. Since then, Palampougioukis' bet has paid off as Tesla's share price has increased more than six-fold, trading around $1,500 on Monday and surpassing every rival to become the world's highest-valued automaker. "To me it didn't feel like a bet because I studied what Tesla does very closely and it's simply inevitable that it would dominate," Palampougioukis said, adding that he plans to own the shares for decades....
If there's any company that can demonstrate the value of diversification in a period of unprecedented economic turmoil, Microsoft Corporation (NASDAQ: MSFT) is arguably one of them.Like most businesses, the software giant took a few sharp hits to some of its core segments during the COVID lockdown earlier this year. But in the end, other segments in MSFT's vast portfolio of services propelled the company to big growth in its fiscal Q3 reported in April, likely stunning analysts and investors expecting positive yet tempered results. As MSFT CEO Satya Nadella told analysts in last quarter's conference call, the COVID-19 pandemic brought "two years' worth of digital transformation in two months."Although nobody can really say just how long the pandemic will last, we do know that it's radically reshaping the way people 'work' and how businesses 'live.' And to this, Nadella boldly claims that MSFT is "the only" one-stop solution to help...
Rapidly accelerating the turnover of the existing fleet to the newest generation of diesel technology as well as expanding the use of low-carbon advanced biofuels can deliver benefits today, and should not be overlooked. ...
Every investor in eXp World Holdings, Inc. (NASDAQ:EXPI) should be aware of the most powerful shareholder groups......
If you want to know who really controls Exelixis, Inc. (NASDAQ:EXEL), then you'll have to look at the makeup of its......
